Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 18/20 | 0.55 |
| ▸ | F3 | P13726 | 17/20 | 0.55 |
| ▸ | F2 | P00734 | 12/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 8/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486413 | 0.84 | F2 (0.46) | F7F3F2F10 | |
| Trifluoroacetic Acid SCHEMBL31486164 | 0.82 | F2 (0.37) | F7F3F2TPSAB1 | |
| SCHEMBL31486457 | 0.81 | F2 (0.46) | F7F3F2 | |
| SCHEMBL31486356 | 0.81 | F2 (0.44) | F7F3F2 | |
| SCHEMBL31486275 | 0.80 | F3 (0.42) | F7F3F2PRSS1PRSS2 | |
| Trifluoroacetic Acid SCHEMBL31486422 | 0.78 | F2 (0.39) | F7F3F2TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL31486347 | 0.74 | F2 (0.39) | F2 | |
| Trifluoroacetic Acid SCHEMBL31486239 | 0.72 | F7 (0.43) | F7F3F2F10 | |
| SCHEMBL31486309 | 0.71 | F2 (0.45) | F3F2 | |
| SCHEMBL8347917 | 0.71 | F7 (1.00) | F7F3F2PRSS1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | F7 1426/4885F3 181/4885F2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.